New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:22 EDTEGLT, CORT, EBS, RPTP, OVAS, DRTXJanney Capital to hold a conference
2nd Annual Healthcare 1x1 Corporate Access Day to be held in Boston on June 26.
News For RPTP;CORT;DRTX;EBS;EGLT;OVAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
16:26 EDTOVASOn The Fly: Closing Wrap
Stocks began the session sharply higher and remained that way for the entire session. The strength was attributed to investor enthusiasm over statements from the Fed about being patient in their approach to raising interest rates. Over the past couple of weeks the price of oil has often dictated the direction of equities, but that was not the case today as a drop in WTI and Brent crude was not followed by a dip in the equity averages. With year-end approaching, money managers may be chasing performance, but they also may be adjusting portfolio’s ahead of tomorrow’s quadruple witching, when market index futures, market index options, stock options, and stock futures all expire. ECONOMIC EVENTS: In the U.S., initial jobless claims fell 6K to 289K in the week ended December 13, versus expectations for 295K first-time claims. Markit's flash December Services PMI reading came in at 53.6, which was below the consensus 56.3 forecast. The Philadelphia Fed survey of business conditions index drop to 24.5 in December from November's unexpectedly high 40.8 reading, though the steep pullback was in-line with the consensus forecast. The November index of leading economic indicators rose 0.6%, as expected. In Europe, U.K. retail sales including auto fuel increased 1.6% in November, widely topping economists' forecast for a 0.4% gain. Germany's Ifo business climate index advanced to 105.5 in December from 104.7 in the prior month, narrowly topping expectations. COMPANY NEWS: Oracle (ORCL) rallied $4.19, or 10.18%, to $45.35 after the company’s second quarter results surpassed consensus estimates. Analyst commentary was mixed, with research firms Canaccord and FBR Capital raising their price targets on the stock to $50 and $48, respectively, while JPMorgan said it expects consensus estimates for Oracle to be reduced and Oppenheimer said that it thinks the transition to the cloud is increasing pressure on the company's financial model and restraining EPS growth. MAJOR MOVERS: Among the notable gainers was OvaScience (OVAS), which rose $8.26, or 23.63%, to $43.22 after the company said it has achieved its 2014 corporate goals to advance its three fertility treatment options and its stock was upgraded to Outperform at Wedbush. Also higher was Tetraphase Pharmaceuticals (TTPH), which gained $4.81, or 14.49%, to $38.00 after a study of the company's eravacycline antibiotic met its primary endpoint and more than one research firm said the trial results make the company a more likely takeover target. Among the noteworthy losers was Silicon Image (SIMG), which dropped $1.84, or 27.3%, to $4.90 after the company warned it expects a year-over-year revenue decline in 2015 of about 10% due to a reduction in mobile design wins at one of its largest customers. Also lower were shares of RCS Capital (RCAP), which fell $1.81, or 15.39%, to $9.95 after its Executive Chairman of the Board, Nicholas Schorsch, was reportedly accused of directing two executives at American Realty Capital Properties (ARCP), where he was formerly the Chairman, to manipulate quarterly financial results. INDEXES: The Dow gained 421.28, or 2.43%, to 17,778.15, the Nasdaq advanced 104.08, or 2.24%, to 4,748.40, and the S&P 500 rose 48.34, or 2.4%, to 2,061.23.
12:26 EDTOVASOn The Fly: Midday Wrap
Subscribe for More Information
10:01 EDTOVASOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTOVASOn The Fly: Pre-market Movers
Subscribe for More Information
08:44 EDTOVASOvaScience price target raised to $54 from $16 at JMP Securities
Subscribe for More Information
07:36 EDTOVASOvaScience price target raised to $56 from $23 at Leerink
Subscribe for More Information
07:31 EDTOVASOvaScience price target raised to $100 from $40 at H.C. Wainwright
Subscribe for More Information
07:16 EDTOVASOvaScience upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
December 17, 2014
07:10 EDTEBSEmergent BioSolutions acquires antibiotics portfolio
Emergent BioSolutions announced that it has acquired the EV-035 series of molecules from Evolva Holding SA. EV-035 is a series of novel small molecule broad spectrum antibiotics of the 4-oxoquinolizine class and targets bacterial type IIa topoisomerase. The lead molecule in the series, GC-072, has demonstrated protection in vivo from lethal B. pseudomallei infection when administered orally. GC-072 is being developed as a potential oral and IV treatment for B. pseudomallei under a three-year, $15M contract with the Defense Threat Reduction Agency, or DTRA, of the U.S. Department of Defense. B. pseudomallei is a gram-negative pathogen classified by the Centers for Disease Control and Prevention as a Category B bioterrorism agent and a priority threat capable of being easily weaponized and disseminated. The scope of the DTRA contract includes investigating GC-072 as a treatment for B. pseudomallei in preclinical in vitro and in vivo studies, conducting formulation, manufacturing and toxicology studies, exploring efficacy in additional multi-drug resistant biodefense and commercial pathogens, and preparing an Investigational New Drug application for submission to the FDA.
07:02 EDTOVASOvaScience advances all three fertility treatment options
Subscribe for More Information
05:24 EDTEBSEmergent BioSolutions to acquire EV-035 series from Evolva
Subscribe for More Information
December 12, 2014
08:39 EDTOVASOvaScience to host investor day
Subscribe for More Information
December 11, 2014
08:35 EDTOVASOvaScience names Arthur Tzianabos as president
Subscribe for More Information
December 10, 2014
11:25 EDTOVASOvaScience has large upside potential, Barron's says
Japan’s incredible demand for fertility treatment coupled with OvaScience's product line that aims to make IVF cheaper and more effective should cause the company's stock to continue to rise in the coming year, Barron's says. Reference Link
December 9, 2014
10:23 EDTOVASOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:29 EDTOVASOvaScience initiated with an Outperform at Credit Suisse
Subscribe for More Information
December 8, 2014
10:42 EDTRPTPOptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use